Alpha 2.0
Login Register
» Authors » Hassan Alkhateeb

Hassan Alkhateeb

Explore the profile of Hassan Alkhateeb including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 73
Citations 296
Followers 0
Related Specialties
Hematology
Oncology
General Surgery
Top 10 Co-Authors
Ayalew Tefferi
Aref Al-Kali
Naseema Gangat
William J Hogan
Mark R Litzow
Animesh Pardanani
Mrinal M Patnaik
Kebede H Begna
Mithun Shah
Abhishek Mangaonkar
Published In
Am J Hematol
Blood Cancer J
Haematologica
Bone Marrow Transplant
Blood Adv
Affiliations
Soon will be listed here.
Recent Articles
1.
T-cell immune cluster analysis using CyTOF identifies unique subgroups of patients with acute myeloid leukemia
Badar T, Knutson K, Knutson K, Foran J, Foran J, Gangat N, et al.
Blood Adv . 2024 Nov; 9(2):239-243. PMID: 39571168
No abstract available.
2.
Clinical outcomes of patients diagnosed with mutated myeloid neoplasms
Jabban Y, Yacout M, Baranwal A, He R, Viswanatha D, Greipp P, et al.
Leuk Lymphoma . 2024 Nov; 66(3):497-506. PMID: 39504138
SETBP1 mutations (m) have been previously reported in myeloid neoplasms and are associated with poor prognostic co-mutations and cytogenetic abnormalities. We retrospectively analyzed the charts of 113 patients diagnosed with...
3.
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol
Palmisiano N, Lee J, Claxton D, Paietta E, Alkhateeb H, Park J, et al.
EJHaem . 2024 Oct; 5(5):951-956. PMID: 39415930
Introduction: Relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL) remains a therapeutic challenge. Preclinical data in both B- and T-ALL suggests synergy of venetoclax (VEN) with...
4.
Characterisation and prognostic impact Of ZRSR2 mutations in myeloid neoplasms
Yacout M, Katamesh B, Jabban Y, He R, Viswanatha D, Jevremovic D, et al.
Leukemia . 2024 Sep; 38(12):2727-2730. PMID: 39313565
No abstract available.
5.
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
Khurana A, Rosenthal A, Mohty R, Gaddam M, Bansal R, Hathcock M, et al.
Blood Cancer J . 2024 Aug; 14(1):136. PMID: 39134524
No abstract available.
6.
Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experience
Tessier S, He R, Greipp P, Viswanatha D, Bessonen K, Lasho T, et al.
Blood Adv . 2024 Jul; 8(18):4807-4811. PMID: 39042872
No abstract available.
7.
genotype-based risk stratification outperforms mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia
Csizmar C, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho T, et al.
Haematologica . 2024 Jun; 109(10):3419-3425. PMID: 38899337
No abstract available.
8.
FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(): the Mayo Clinic experience
Csizmar C, Saliba A, Greipp P, Alkhateeb H, Begna K, Foran J, et al.
Haematologica . 2024 Jun; 109(11):3785-3789. PMID: 38899336
No abstract available.
9.
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance
Li M, Baranwal A, Gurney M, Shah S, Al-Kali A, Alkhateeb H, et al.
Blood Adv . 2024 Apr; 8(12):3130-3139. PMID: 38564774
Clonal cytopenia of undetermined significance (CCUS) is defined by a myeloid driver mutation in the context of otherwise unexplained cytopenia. CCUS has an inherent risk of progressing to myeloid neoplasm....
10.
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
Johnson I, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, et al.
Br J Haematol . 2024 Feb; 204(4):1232-1237. PMID: 38311378
Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non-ST elevation myocardial infarction and/or 7...